Tolterodine (Monograph)
Brand name: Detrol
Drug class: Antimuscarinics
VA class: AU350
Chemical name: (R)-2-[3-[Bis(1-methylethyl)amino]-1-phenylpropyl]-4-methylphenol [R-(R*,R*)]-2,3-dihydroxybutanedioate (1:1) salt
Molecular formula: C22H31NO•C4H6O6
CAS number: 124937-52-6
Introduction
Genitourinary antispasmodic agent; a synthetic tertiary amine antimuscarinic agent.
Uses for Tolterodine
Overactive Bladder
Treatment of overactive bladder for the relief of symptoms associated with voiding such as urge urinary incontinence, urgency, and frequency. Efficacy not established in pediatric patients.
Tolterodine (conventional tablets) appears to be as effective as conventional oxybutynin in reducing urinary symptoms in patients with overactive bladder and is associated with a lower incidence of dry mouth.
Tolterodine (2 mg twice daily as conventional tablets) appears to be less effective than extended-release oxybutynin (10 mg once daily as extended-release tablets) in reducing urinary symptoms in patients with overactive bladder. The incidence of adverse effects (e.g., dry mouth) is similar between conventional tolterodine tartrate and extended-release oxybutynin.
Single daily doses of extended-release capsules of tolterodine tartrate appear to be slightly more effective in relieving certain urinary symptoms (i.e., urge incontinence) than 2 daily doses of conventional tablets of the drug.
Tolterodine Dosage and Administration
Administration
Oral Administration
Administer orally without regard to meals. (See Food under Pharmacokinetics.) Some clinicians recommend administering tolterodine tartrate in a consistent manner relative to food intake.
Extended-release capsules should be administered with adequate amounts of fluid and swallowed whole.
Dosage
Available as tolterodine tartrate; dosage expressed in terms of the salt.
Adults
Overactive Bladder
Oral
Conventional tablets: Initially, 2 mg twice daily. May reduce dosage to 1 mg twice daily according to individual response and tolerance.
Extended-release capsules: Initially, 4 mg once daily. May reduce dosage to 2 mg once daily according to individual response and tolerance; however, efficacy data for this lower dosage are limited.
Special Populations
Renal Impairment
1 mg twice daily (as conventional tablets) or 2 mg once daily (as extended-release capsules) in patients with substantially reduced renal function.
Hepatic Impairment
1 mg twice daily (as conventional tablets) or 2 mg once daily (as extended-release capsules) in patients with substantially reduced hepatic function.
Geriatric Patients
No dosage adjustments required for otherwise healthy geriatric patients. (See Geriatric Use under Cautions.)
Cautions for Tolterodine
Contraindications
-
Urinary retention.
-
Gastric retention.
-
Uncontrolled angle-closure glaucoma.
-
Known hypersensitivity to tolterodine or any ingredient in the formulation.
Warnings/Precautions
Sensitivity Reactions
Anaphylactoid reactions (e.g., angioedema) reported during postmarketing surveillance; however, a causal relationship not established.
General Precautions
Urinary or Gastric Retention
Risk of urinary or gastric retention; use with caution in patients with clinically important bladder outflow obstruction or GI obstructive disorders (e.g., pyloric stenosis).
Decreased GI Motility
Use with caution in patients with decreased GI motility.
Angle-closure Glaucoma
Use with caution in patients receiving therapy for angle-closure glaucoma.
Myasthenia Gravis
Use with caution in patients with myasthenia gravis.
Cardiovascular Effects
Prolongation of QTc interval observed following administration of therapeutic (2 mg twice daily) and supratherapeutic (4 mg twice daily) dosages in healthy adults. Effect is more pronounced with 8-mg daily dosage and in individuals with poor-oxidizer phenotype. The 8-mg daily dosage also associated with more pronounced increase in heart rate than 4-mg daily dosage. Associated torsades de pointes not reported during postmarketing experience.
Consider effect on QTc interval when deciding to use tolterodine in patients with history of QT interval prolongation or in those receiving class IA (e.g., quinidine, procainamide) or class III (e.g., amiodarone, sotalol) antiarrhythmic agents.
Specific Populations
Pregnancy
Category C.
Lactation
Distributed into milk in mice; not known whether distributed into human milk. Discontinue nursing or the drug.
Pediatric Use
Efficacy not established in children <18 years of age.
In patients 5–10 years of age with urinary frequency and urge incontinence, incidence of urinary tract infections was higher following therapy with tolterodine extended-release capsules than with placebo (6.6 versus 4.5%). Aggressive, abnormal, and hyperactive behavior and attention disorders reported in 2.9% of patients receiving extended-release capsules compared with 0.9% of those receiving placebo.
Geriatric Use
No substantial differences in safety relative to younger adults. (See Absorption: Special Populations, under Pharmacokinetics.) Aggravation of symptoms of dementia (e.g., confusion, disorientation, delusion) reported during postmarketing experience after initiation of tolterodine in patients taking acetylcholinesterase inhibitors for the treatment of dementia.
Renal or Hepatic Impairment
Renal or hepatic impairment may substantially affect the disposition of tolterodine; dosage reduction necessary in patients with substantially reduced renal or hepatic function. (See Renal and Hepatic Impairment under Dosage and Administration.)
Common Adverse Effects
Dry mouth, headache, constipation, abdominal pain, vertigo/dizziness.
Drug Interactions
Appears to be metabolized principally by CYP2D6 in individuals with the extensive-oxidizer phenotype (i.e. those with CYP2D6); metabolized by CYP3A4 in individuals with the poor-oxidizer phenotype (i.e. those devoid of CYP2D6).
Does not inhibit CYP1A2, 2D6, 2C9, 2C19, or 3A4; however, may inhibit CYP2D6 at high concentrations.
Drugs Affecting Hepatic Microsomal Enzymes
Inhibitors of CYP2D6: Potential pharmacokinetic interaction (increased tolterodine concentrations).
Inhibitors of CYP3A4: Potential pharmacokinetic interaction (increased tolterodine concentrations). (See Specific Drugs under Interactions.)
Specific Drugs
Drug |
Interaction |
Comment |
---|---|---|
Acetylcholinesterase inhibitors |
Aggravation of symptoms of dementia (e.g., confusion, disorientation, delusion) reported |
Some clinicians recommend avoidance of tolterodine in dementia patients receiving acetylcholinesterase inhibitors |
Antiarrhythmic agents (e.g., amiodarone, procainamide, quinidine, sotalol) |
Possible prolongation of QTc interval |
Consider potential for prolongation of QTc when contemplating concomitant therapy |
Anticoagulants (e.g., warfarin) |
No effect on PT, suppression of factor VII, or warfarin pharmacokinetics observed when a single 25-mg dose of warfarin was administered on day 4 of tolterodine therapy; however, increased INR has been reported with concomitant use |
|
Antimuscarinic agents |
Possible increased antimuscarinic effects |
|
Azole antifungals (itraconazole, ketoconazole, miconazole) |
Possible increased tolterodine concentrations |
Reduce tolterodine dosage to 1 mg twice daily (as conventional tablets) or 2 mg once daily (as extended-release capsules) |
Cyclosporine |
Possible increased tolterodine concentrations |
Reduce tolterodine dosage to 1 mg twice daily (as conventional tablets) or 2 mg once daily (as extended-release capsules) |
Diuretics |
No ECG abnormalities reported when conventional tablets were given concomitantly with bendroflumethiazide, chlorothiazide, furosemide, indapamide, hydrochlorothiazide, methyclothiazide, or triamterene |
|
Fluoxetine |
Possible increased tolterodine concentrations |
No dosage adjustment needed since concentrations of unbound drug and metabolite are only modestly increased |
Macrolide antibiotics (e.g., erythromycin, clarithromycin) |
Possible increased tolterodine concentrations |
Reduce tolterodine dosage to 1 mg twice daily (as conventional tablets) or 2 mg once daily (as extended-release capsules) |
Oral contraceptives |
Pharmacokinetic interaction with estrogen-progestin contraceptives unlikely |
|
Vinblastine |
Possible increased tolterodine concentrations |
Reduce tolterodine dosage to 1 mg twice daily (as conventional tablets) or 2 mg once daily (as extended-release capsules) |
Tolterodine Pharmacokinetics
Absorption
Bioavailability
≥77% of a dose is absorbed rapidly from the GI tract.
Absolute oral bioavailability is variable (10–74%) and may depend on a patient’s genetically determined ability to metabolize the drug. The absolute bioavailability is higher in individuals with the poor-oxidizer phenotype (i.e. those devoid of CYP2D6) than that in patients with the extensive-oxidizer phenotype (i.e. those with CYP2D6).
Peak and trough serum tolterodine concentrations achieved with extended-release capsules are approximately 75 and 150%, respectively, of those achieved with conventional tablets.
Peak serum concentrations usually occur within 1–2 hours following administration of conventional tablets or 2–6 hours following administration of extended-release capsules.
Onset
Following oral administration in healthy men, inhibitory effects on urinary bladder function were observed within 1 hour.
Duration
Following oral administration in healthy men, inhibitory effects on urinary bladder function persisted for at least 5 hours.
Food
Food may increase oral bioavailability of conventional tablets; however, such changes are not expected to be clinically important. Food does not appear to alter the pharmacokinetics of extended-release capsules. (See Administration under Dosage and Administration.)
Special Populations
In geriatric adults receiving conventional tablets, serum concentrations of tolterodine and 5-hydroxymethyl metabolite (5-hydroxymethyl tolterodine) may be similar or possibly higher than those observed in younger adults. (See Geriatric Use under Cautions.)
Following administration of extended-release capsules, pediatric patients (11–15 years of age) with the extensive-oxidizer phenotype have low serum concentrations of tolterodine and high concentrations of 5-hydroxymethyl metabolite, while patients with the poor-oxidizer phenotype had high concentrations of tolterodine and negligible concentrations of 5-hydroxymethyl metabolite.
In patients with renal impairment, serum concentrations of tolterodine tartrate and 5-hydroxymethyl metabolite following administration of conventional tablets are twofold to threefold or higher than in healthy individuals. (See Renal Impairment under Dosage and Administration.)
Distribution
Extent
Distribution of tolterodine not fully characterized. Tolterodine and its 5-hydroxymethyl metabolite do not appear to distribute extensively into erythrocytes.
Distributed into milk in mice; not known whether tolterodine crosses the placenta or is distributed into human milk.
Plasma Protein Binding
Tolterodine: approximately 96.3% (mainly α1-acid glycoprotein. )
5-hydroxymethyl metabolite: approximately 64%.
Elimination
Metabolism
Undergoes extensive first-pass metabolism in the liver by CYP2D6 to 5-hydroxymethyl tolterodine (active metabolite) in individuals with the extensive-oxidizer phenotype. (Fesoterodine, another antimuscarinic agent used in the treatment of overactive bladder, also is metabolized to 5-hydroxymethyl tolterodine; however, fesoterodine metabolism to 5-hydroxymethyl tolterodine is via nonspecific esterases.)
Metabolized by CYP3A4 to N-dealkylated tolterodine (inactive metabolite) in individuals with the poor-oxidizer phenotype (i.e. those devoid of CYP2D6); undergoes only limited first-pass metabolism in these individuals.
Approximately 93% of Caucasians exhibit the extensive-oxidizer phenotype and about 7% exhibit the poor-oxidizer phenotype.
Elimination Route
Following oral administration, approximately 77 and 17% of administered dose was recovered within 7 days in urine and feces, respectively, principally within the first 24 hours.
Half-life
Preparation |
Drug or Metabolite |
Elimination Half-life in Individuals with Extensive-Oxidizer Phenotype |
Elimination Half-life in Individuals with Poor-Oxidizer Phenotype |
---|---|---|---|
Conventional Tablets |
Tolterodine |
2–2.4 hours |
6.5–9.6 hours |
5-Hydroxymethyl metabolite |
2.9–3.1 hours |
N/A |
|
Extended-Release Capsules |
Tolterodine |
6.9–8.4 hours |
13 hours |
5-Hydroxymethyl metabolite |
8.8–9.9 hours |
N/A |
Special Populations
Elimination half-life of tolterodine prolonged in patients with hepatic impairment. (See Hepatic Impairment under Dosage and Administration.)
Stability
Storage
Oral
Extended-Release Capsules and Conventional Tablets
25°C (may be exposed to 15–30°C).
Actions
-
Nonselective competitive antagonist at muscarinic receptors present in the bladder, salivary glands, and other organs.
-
Generally exhibits pharmacologic actions similar to those of other antimuscarinics.
-
Decreases contraction of the detrusor muscle of normal and overactive urinary bladder and increases volumes of residual urine.
-
May cause inhibition of salivation. (See Common Adverse Effects under Cautions.)
-
Little or no activity at α-adrenergic receptors, histaminergic receptors, calcium-channel receptors, and the neuromuscular junction.
Advice to Patients
-
Risk of blurred vision, dizziness, or drowsiness. Use caution when engaging in potentially hazardous activities until effects on individual are known.
-
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs and herbal supplements, as well as any concomitant illnesses.
-
Importance of women informing their clinician if they are or plan to become pregnant or plan to breast-feed.
-
Importance of informing patients of other important precautionary information. (See Cautions.)
Preparations
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.
Routes |
Dosage Forms |
Strengths |
Brand Names |
Manufacturer |
---|---|---|---|---|
Oral |
Capsules, extended-release |
2 mg |
Detrol LA |
Pfizer |
4 mg |
Detrol LA |
Pfizer |
||
Tablets, film-coated |
1 mg |
Detrol |
Pfizer |
|
2 mg |
Detrol |
Pfizer |
AHFS DI Essentials™. © Copyright 2025, Selected Revisions May 1, 2010. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.
Reload page with references included
More about tolterodine
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (76)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: urinary antispasmodics
- Breastfeeding
- En español
Patient resources
Professional resources
- Tolterodine Tartrate Capsules prescribing information
- Tolterodine Tartrate ER Tablets (FDA)
- Tolterodine Tartrate Tablets (FDA)